SMTL ID : 5pgv.1 (1 other biounit)

CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 1-(3-HYDROXYAZETIDIN-1-YL)-2-[(2S,5R)-2-(4-FLUOROPHENYL)-5-METHOXYADAMANTAN-2-YL]ETHAN-1-ONE

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.35 Å

Oligo State

homo-dimer

Ligands

2 x NAP: NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)

NAP.1: 31 residues within 4Å: Chain A: G.35, A.36, S.37, K.38, G.39, I.40, A.59, R.60, S.61, G.85, T.86, M.87, E.88, N.113, H.114, I.115, N.117, Y.141, V.162, S.163, S.164, Y.177, K.181, L.209, G.210, L.211, I.212, T.214, T.216, A.217 Ligands: 8K7.2 29 PLIP interactions: 29 interactions with chain A Hydrophobic interactions: A:L.209 Hydrogen bonds: A:G.35, A:S.37, A:S.37, A:S.37, A:K.38, A:I.40, A:R.60, A:S.61, A:T.86, A:M.87, A:E.88, A:N.113, A:I.115, A:V.162, A:Y.177, A:K.181, A:I.212, A:I.212, A:T.216 Water bridges: A:K.38, A:G.39, A:G.41, A:S.61, A:S.61, A:N.117, A:T.214 Salt bridges: A:K.38, A:R.60 NAP.3: 31 residues within 4Å: Chain B: G.35, A.36, S.37, K.38, G.39, I.40, A.59, R.60, S.61, G.85, T.86, M.87, E.88, N.113, H.114, I.115, N.117, Y.141, V.162, S.163, S.164, Y.177, K.181, L.209, G.210, L.211, I.212, T.214, T.216, A.217 Ligands: 8K7.4 29 PLIP interactions: 29 interactions with chain B Hydrophobic interactions: B:L.209 Hydrogen bonds: B:G.35, B:S.37, B:S.37, B:S.37, B:K.38, B:I.40, B:R.60, B:R.60, B:S.61, B:T.86, B:M.87, B:N.113, B:Y.177, B:K.181, B:K.181, B:I.212, B:I.212, B:T.214, B:T.216 Water bridges: B:K.38, B:G.41, B:G.41, B:R.60, B:T.116, B:T.116, B:T.116, B:T.216 Salt bridges: B:R.60

2 x 8K7: 1-(3-HYDROXYAZETIDIN-1-YL)-2-[(2S,5R)-2-(4-FLUOROPHENYL)-5-METHOXYADAMANTAN-2-YL]ETHAN-1-ONE(Non-covalent)

8K7.2: 20 residues within 4Å: Chain A: I.115, T.118, S.119, L.120, S.164, L.165, A.166, Y.171, V.174, Y.177, L.209, G.210, L.211, T.214, T.216, A.217, A.220, V.221, V.225 Ligands: NAP.1 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:V.174, A:Y.177, A:Y.177, A:A.217, A:A.220, A:V.221 Hydrogen bonds: A:S.164, A:Y.171, A:L.211 8K7.4: 20 residues within 4Å: Chain B: I.115, T.118, S.119, L.120, S.164, L.165, A.166, Y.171, V.174, Y.177, L.209, G.210, L.211, T.216, A.217, A.220, V.221, V.225, M.227 Ligands: NAP.3 10 PLIP interactions: 10 interactions with chain B Hydrophobic interactions: B:T.118, B:V.174, B:Y.177, B:Y.177, B:A.217, B:A.220, B:V.221, B:V.225 Hydrogen bonds: B:S.164, B:L.211

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ye, X.Y. et al., Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11 beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J. Med. Chem. (2017)

Release Date

2017-11-01

Peptides

Corticosteroid 11-beta-dehydrogenase isozyme 1: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Corticosteroid 11-beta-dehydrogenase isozyme 1

Related Entries With Identical Sequence